Marjorie Taylor Greene
Marjorie Taylor Greene (R-GA) bought $15K-$50K of $MELI (MercadoLibre, Inc. - Common Stock (MELI)) on May 14, 2025, part of 21 transactions in this filing.
HillSignal flagged 5 timing concerns on this filing — trades that line up closely with related legislative or contract activity.
Companies in this filing · 19
Price Movement Since Trade
How the largest positions have moved from the trade date to the most recent close.
Showing the 6 largest positions. See every transaction in the table below.
Sign Up to See More
See the full trade breakdown, suspicious timing flags, and how this filing connects to active legislation.
Get Free Access →Suspicious Timing Detected
5 flagsMarjorie Taylor Greene bought $1,001 - $15,000 in $LLY on 2025-05-14, 5 days before the DeOndra Dixon INCLUDE Project Act of 2025 (HR3491) was introduced and referred to the Committee on Energy and Commerce.
Marjorie Taylor Greene bought $1,001 - $15,000 in $NVDA on 2025-05-14, 8 days before the Access Technology Affordability Act of 2025 (S1918) was introduced, which proposes a tax credit for assistive technology.
Marjorie Taylor Greene bought $1,001 - $15,000 in $AMGN on 2025-05-14, 22 days before the Treat and Reduce Obesity Act of 2025 (S1973) was introduced, aiming to expand Medicare coverage for obesity treatments.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | Treasury Bill | US Treasury Bill(Treasury Bill) | $100K-$250K | — | — | — | May 16, 2025 |
| BUY | $MELI | MercadoLibre, Inc. - Common Stock (MELI) | $15K-$50K | $2,564.00 | $1,835.22 | -28.4% | May 14, 2025 |
| BUY | $UNH | UnitedHealth Group Incorporated Common Stock (UNH) | $15K-$50K | $308.01 | — | — | May 14, 2025 |
| BUY | $AMD | Advanced Micro Devices, Inc. (AMD) | $1K-$15K | $117.72 | $347.81 | +195.5% | May 14, 2025 |
| BUY | $GOOG | Alphabet Inc. - Class C Capital Stock (GOOG) | $1K-$15K | $166.81 | — | — | May 14, 2025 |
| BUY | $AMGN | Amgen Inc. - Common Stock (AMGN) | $1K-$15K | $262.28 | — | — | May 14, 2025 |
| BUY | $BX | Blackstone Inc. Common Stock (BX) | $1K-$15K | $148.42 | — | — | May 14, 2025 |
| BUY | $CAH | Cardinal Health, Inc. Common Stock (CAH) | $1K-$15K | $148.41 | — | — | May 14, 2025 |
| BUY | $CVX | Chevron Corporation Common Stock (CVX) | $1K-$15K | $141.67 | $185.21 | +30.7% | May 14, 2025 |
| BUY | $GLW | Corning Incorporated Common Stock (GLW) | $1K-$15K | $47.01 | — | — | May 14, 2025 |
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Stop the Scroll Act
The Stop the Scroll Act (S.1885) is a bearish catalyst for ad-revenue-dependent social media platforms. Despite recent rallies, this bill mandates FTC/Surgeon General warning labels on platforms like those owned by META, SNAP, and PINS. Real market data shows META dropped -10.36% in the past 7 days, while SNAP and PINS remain off their 52-week highs, indicating market sensitivity to regulatory risk.
Treat and Reduce Obesity Act of 2025
The Treat and Reduce Obesity Act of 2025 would mandate Medicare Part D coverage of GLP-1 obesity drugs, unlocking a massive new payer market of ~27 million beneficiaries. $NVO and $LLY are the two direct beneficiaries. The bill is in early-stage committee referral with 22 bipartisan cosponsors; no companion bill has passed the House yet. Real market data shows $NVO gaining 15.56% over 30 days vs $LLY's +0.7%, suggesting the market may be overweighting Novo's near-term Medicare exposure given its larger U.S. obesity market share.
DeOndra Dixon INCLUDE Project Act of 2025
HR3491 (DeOndra Dixon INCLUDE Project Act) authorizes a Down syndrome research program at NIH but appropriates zero funding. With only 5 procedural actions over a year and stalled committee markup, the bill has no near-term market impact. No public companies are directly affected.
Lowering Broadband Costs for Consumers Act of 2025
HR4032 (Lowering Broadband Costs for Consumers Act) is an early-stage bill that would expand USF contribution requirements to broadband and edge providers. It remains in committee with no floor action, making near-term market impact negligible. If passed, $CMCSA, $T, $VZ, $GOOGL, $META, $AMZN, and $NFLX would face new recurring costs reducing segment margins by an estimated 1-3%.
Supporting Healthy Moms and Babies Act
The 'Supporting Healthy Moms and Babies Act' (HR3762) is an early-stage bill that would mandate comprehensive maternity/newborn care coverage without cost-sharing under ACA plans. With 28 cosponsors, a companion bill in the Senate, and referral to three committees, legislative progress is early but has nominal bipartisan support. Insurers UNH and CI face increased medical costs, while diagnostic labs LH and DGX benefit from higher utilization. No dollar amount is authorized or appropriated.
Small Biotech Innovation Act
The Small Biotech Innovation Act (HR3731) is an early-stage bill that would exempt R&D-intensive small biotech manufacturers (≤5 qualifying drugs) from Medicare drug price negotiations starting in 2029. The bill is in committee with no floor action, and no market reaction is evident from provided data. The legislative path is long and uncertain — this is a structural watch item, not a trading catalyst.
Association Health Plans Act
S.1847 is an early-stage bill expanding self-funded association health plans for small businesses, structurally negative for fully insured commercial carriers. The bill has no dollar authorization and remains in committee with only 6 sponsors — near-term passage probability is low. Real market data shows large health insurers (UNH, HUM, CVS, CNC) surging 15-55% in the last 30 days, but this rally is unrelated to S.1847 and driven by broader sector dynamics.
Access Technology Affordability Act of 2025
S. 1918 is an early-stage, low-probability bill proposing a refundable tax credit for blind individuals purchasing access technology. It creates no direct revenue stream for any public company and has negligible near-term market impact.
RAMP Act
The RAMP Act (HR4056) is an early-stage bill that would restrict the Medicare Secondary Payer private right of action to group health plans only, granting legal relief to auto, liability, workers' compensation, and no-fault insurers. The bill is referenced to two committees and has only one cosponsor, indicating a long legislative path. For the named insurers—UnitedHealth, Cigna, Humana—the bill is largely neutral as they primarily operate group health plans, which retain existing litigation exposure.
Tackling Predatory Litigation Funding Act
HR3512, the Tackling Predatory Litigation Funding Act, proposes a 40.8% federal excise tax on litigation finance proceeds, directly targeting third-party funders. The bill is in early legislative stages, but the structural threat has already contributed to recent price declines in $BX, $KKR, and $APO. Investors should monitor committee markup for signs of momentum.
Other Filings by Marjorie Taylor Greene
Free — no credit card
Get the next Greene trade the day it's disclosed
HillSignal tracks every Congressional stock filing and federal contract, scores its market impact with AI, and emails you the ones that matter — before they hit the news.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.